| 发明名称 |
Use of 1-{4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl}-azetidine-3-carboxylic acid in treating symptoms associated with rett syndrome |
| 摘要 |
Use of an S1P receptor modulator in the treatment or prevention of a disease or condition dependent on brain-derived neurotrophic factor (BDNF) expression. |
| 申请公布号 |
US9265754(B2) |
申请公布日期 |
2016.02.23 |
| 申请号 |
US201314097623 |
申请日期 |
2013.12.05 |
| 申请人 |
Novartis AG |
发明人 |
Barde Yves-Alain;Bilbe Graeme;Deogracias Ruben;Kuhn Rainer R.;Matsumoto Tomoya;Mir Anis Khusro;Schubart Anna Svenja |
| 分类号 |
A61K31/397;A61K31/138;A61K31/145;A61K31/137;A61K45/06 |
主分类号 |
A61K31/397 |
| 代理机构 |
|
代理人 |
Lynch James |
| 主权项 |
1. A method for treating one or more symptoms associated with Rett Syndrome, in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of 1-{4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl}-azetidine-3-carboxylic acid. |
| 地址 |
Basel CH |
